Submission of certificate of extinguishment of 5423728 equity shares of Re.1/- of the Company bought back from the shareholders of the Company under Buyback Offer.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma has completed its share buyback programme by extinguishing 54,23,728 equity shares (approximately 54.24 lakh shares) on May 14, 2026. The buyback was conducted via a tender offer route at ₹1,475 per share, with a maximum outlay of ₹800 crore. The shares were bought back from the open market during the tendering period from April 23 to April 29, 2026. Post-extinguishment, the company's paid-up share capital has reduced from 58,08,01,623 shares (₹58.08 crore) to 57,53,77,895 shares (₹57.54 crore). NSDL and CDSL have confirmed the extinguishment, and the process complies with SEBI Buy-Back Regulations.
The buyback reduces outstanding shares by ~0.93%, which is earnings-accretive for remaining shareholders. Promoter holding rose marginally from 51.82% to 51.88%, indicating non-promoters participated slightly more in tendering. This is a routine positive signal of cash deployment and shareholder returns.